Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Treatment in older patients with CLL or SLL can be challenging due to likelihood of comorbidities, Atanasio says. Previous studies show that the combination of chlorambucil with obinutuzumab improved progression-free and overall survival in patients with comorbidities. However, it did not show a benefit in patients with poor prognosis or who had a 17p deletion.

The multicenter randomized phase III study comparing the combinations of ibrutinib and obinutuzumab with chlorambucil and obinutuzumab has not yet begun enrolling patients. Results of the study, Atanasio says, could potentially identify new treatments for patients who are ineligible for chemoimmunotherapy.

View more from the 13th International Conference on Malignant Lymphoma

Videos

Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naÃ¯ve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). 

Carolina Moreno Atanasio, MD

Articles

Dr. Atanasio on Ibrutinib and Obinuzutumab Combination in CLL/SLL